Test Code MPSWB Mucopolysaccharidosis, Blood
Specimen Required
Patient Preparation: Do not administer low-molecular weight heparin prior to collection.
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 2 mL
CMH COLLECTION: 2 mL in EDTA lavender vacutainer
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole blood | Ambient (preferred) | 7 days | |
Refrigerated | 7 days |
Testing Algorithm
If the patient has abnormal newborn screening result for mucopolysaccharidosis type I, immediate action should be taken. Refer to the appropriate American College of Medical Genetics and Genomics Newborn Screening ACT Sheet.(1)
For more information, see the following:
 Newborn Screen Follow-up for Mucopolysaccharidosis Type I.
-Newborn Screening Follow up for Mucopolysaccharidosis type II
Useful For
Supporting the biochemical diagnosis of mucopolysaccharidoses type I, II, III, IV, or VI
Quantification of heparan sulfate, dermatan sulfate, and keratan sulfate in whole blood specimens
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Day(s) Performed
Monday, Wednesday, Friday
Report Available
3 to 5 daysReporting Name
Mucopolysaccharidosis, BReference Values
DERMATAN SULFATE (DS)
Newborn-≤2 weeks: ≤200 nmol/L
>2 weeks: ≤130 nmol/L
HEPARAN SULFATE (HS)
Newborn-≤2 weeks: ≤96 nmol/L
>2 weeks: ≤95 nmol/L
TOTAL KERATAN SULFATE (KS)
≤5 years: ≤1900 nmol/L
6-10 years: ≤1750 nmol/L
11-15 years: ≤1500 nmol/L
>15 years: ≤750 nmol/L
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Performing Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
83864